NCT05272059

Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus

Name: Clinical Trial NCT05272059
Creator: Novartis Pharmaceuticals
Keywords: Type 1 Diabetes Mellitus, MHS552, Phase 1, drug, clinical trial

A Randomized, Investigator and Participant Blinded, Placebo Controlled, Multiple Ascending Dose, Two Part Design Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of MHS552 in Adults With Type 1 Diabetes Mellitus (T1DM)

Novartis Pharmaceuticals·Phase 1·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Type 1 Diabetes Mellitus
Drug/Device/Intervention: MHS552
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Novartis Pharmaceuticals
Funder: Novartis

Timeline & enrollment

Phase: Phase 1
Start date: Feb 13, 2023
End date: Apr 14, 2025
Enrollment: 28 participants

Primary outcome

Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)

Summary

The purpose of this two-part multiple ascending dose study is to evaluate the safety and tolerability of multiple doses of MHS552 in adults with type 1 diabetes mellitus. Participants will be treated for 4 or 12 weeks followed by an 8 week follow-up period

ICD-10 classifications

Type 1 diabetes mellitusType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with multiple complications

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05272059
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05272059 through Pure Global AI's free database. This Phase 1 trial is sponsored by Novartis Pharmaceuticals and is currently Not yet recruiting. The study focuses on Type 1 Diabetes Mellitus. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.